Estatísticas Básicas
| LEI | 549300512PURS7IGVT96 |
| CIK | 1556263 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Syros Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Esta página fornece uma lista completa e cronológica de Arquivamentos da SEC, excluindo os arquivamentos de propriedade que fornecemos em outro lugar.
| March 20, 2025 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-37813 SYROS PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 S-8 POS As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 POS AM As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 S-8 POS As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 S-8 POS As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 POS AM As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 S-8 POS As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 S-8 POS As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 S-8 POS As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 S-8 POS As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 POS AM As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 POS AM As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 S-8 POS As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 S-8 POS As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 S-8 POS As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 POS AM As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37813 Syros Pharmaceuticals, Inc. The Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registere |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 POS AM As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 POS AM As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 28, 2025 |
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration Exhibit 99.1 Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration CAMBRIDGE, Mass., February 28, 2025 – Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market (“Nasdaq”) and the deregistration of |
|
| February 14, 2025 |
SYRS / Syros Pharmaceuticals, Inc. / Avidity Partners Management LP Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No. |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 6, 2024 |
CONFIDENTIAL FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.1 CONFIDENTIAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of Decemb |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 14, 2024 |
SYRS / Syros Pharmaceuticals, Inc. / Avidity Partners Management LP Passive Investment SC 13G/A 1 d1153022213g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87184Q206 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| November 14, 2024 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.A 2 d904884dex99a.htm EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree as follows: i. Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and ii. Each of them is responsible for the timely filing of such Schedule 13G and any amendments ther |
|
| November 14, 2024 |
SYRS / Syros Pharmaceuticals, Inc. / Blue Owl Capital Holdings LP - SC 13G/A Passive Investment SC 13G/A 1 ef20038688sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87184Q206 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| November 14, 2024 |
SC 13G/A 1 d904884dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 4) SYROS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0 |
|
| November 13, 2024 |
EX-99.1 Exhibit 99.1 November 12, 2024 Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression — SELECT-MDS-1 Did Not Meet its Primary Endpoint — — Company to Discontinue Study, Review Full Data Set, and Evaluate Next Steps — CAMBRIDGE, Mass.—(BUSINESS WIRE)— Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmac |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 12, 2024 |
EX-99.1 2 d762034dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the securities of Syros Pharmaceuticals, Inc. is, and any amendments thereto signed by each or any of the undersigned shall be, filed on behalf of each of such person pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exc |
|
| November 12, 2024 |
SYRS / Syros Pharmaceuticals, Inc. / Invus Global Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 d762034dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 4) Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87184Q107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. (Exact Name |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2024 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 5, 2024 |
EX-99.1 Exhibit 99.1 SOCIETY OF HEMATOLOGIC ONCOLOGY 12TH ANNUAL MEETING • September 4—7, 2024 • George R. Brown Convention Center • Houston, Texas SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy Uma Borate MD1, Christine |
|
| August 12, 2024 |
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial EX-99.1 Exhibit 99.1 Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial CAMBRIDGE, Mass., August 12, 2024 – Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the tripl |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 2, 2024 |
EX-99.1 2 d820713dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the securities of Syros Pharmaceuticals, Inc. is, and any amendments thereto signed by each or any of the undersigned shall be, filed on behalf of each of such person pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exc |
|
| August 2, 2024 |
SYRS / Syros Pharmaceuticals, Inc. / Invus Global Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 d820713dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 3) Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87184Q107 (CUSIP Number) July 25, 2024 (Date of Event Which Requires Filing of this Statement) Che |
|
| July 31, 2024 |
As filed with the Securities and Exchange Commission on July 31, 2024 S-8 As filed with the Securities and Exchange Commission on July 31, 2024 Registration No. |
|
| July 31, 2024 |
Exhibit 10.2 SYROS PHARMACEUTICALS, INC. 2022 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this 2022 Equity Incentive Plan (the “Plan”) of Syros Pharmaceuticals, Inc. a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the C |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. (Exact Name of R |
|
| July 31, 2024 |
Restated Certificate of Incorporation of the Registrant, as amended Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF SYROS PHARMACEUTICALS, INC. (originally incorporated on November 9, 2011 under the name LS22, Inc.) First: The name of the Corporation is Syros Pharmaceuticals, Inc. Second: The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, |
|
| July 31, 2024 |
Calculation of Filing Fee Tables EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Syros Pharmaceuticals, Inc. |
|
| July 31, 2024 |
Exhibit 10.1 CONFIDENTIAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, th |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. (Exact Name of |
|
| May 14, 2024 |
Amended and Restated Director Compensation Policy SYROS PHARMACEUTICALS, INC. AMENDED AND RESTATED DIRECTOR COMPENSATION POLICY Non-employee directors shall receive the following compensation for their service as members of the Board of Directors (the “Board”) of Syros Pharmaceuticals, Inc. (the “Company”). Director Compensation Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract and retain ou |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 23, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 23, 2024 |
2023 ANNUAL REPORT $QH[SUHVVLRQPDNHVDZRUOGRIGLႇHUHQFHDear Fellow Shareholders, 2023 was a transformative year for Syros, as we made critical progress in advancing tamibarotene through late-stage development for the frontline treatment of higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). |
|
| April 12, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 27, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name of Entity Jurisdiction of Incorporation Percent Owned by the Registrant Syros Securities Corporation Massachusetts 100% Syros Pharmaceuticals (Ireland) Limited Ireland 100% Tyme Technologies, Inc. Delaware 100% Tyme, Inc. Delaware 100% |
|
| March 27, 2024 |
35 CambridgePark Drive, 4th Floor Cambridge, MA 02140 www.syros.com CONFIDNTIAL October 16, 2023 Eric R. Olson, Ph.D. By Electronic Mail Re: Separation Agreement Dear Eric: The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your separation from Syros Pharmaceuticals, Inc. (“Syros” or “the Company”). We appreciate your contributions to the Company and wish you the b |
|
| March 27, 2024 |
Dodd-Frank Compensation Recovery Policy Exhibit 97.1 Syros Pharmaceuticals, Inc. Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Syros Pharmaceuticals, Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Do |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37813 SYROS PHARMACEU |
|
| March 27, 2024 |
As filed with the Securities and Exchange Commission on March 27, 2024 As filed with the Securities and Exchange Commission on March 27, 2024 Registration No. |
|
| March 27, 2024 |
Description of Securities Registered under Section 12 of the Exchange Act Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the common stock, par value $0.001 per share (the “Common Stock”) of Syros Pharmaceuticals, Inc. (“us,” “our,” “we” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), summari |
|
| March 27, 2024 |
Calculation of Filing Fee Tables EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Syros Pharmaceuticals, Inc. |
|
| February 14, 2024 |
US87184Q2066 / Syros Pharmaceuticals Inc / Blue Owl Capital Holdings LP - SC 13G Passive Investment SC 13G 1 ef20021767sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87184Q206 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the App |
|
| February 13, 2024 |
US87184Q2066 / Syros Pharmaceuticals Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d1098044713g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87184Q206 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 13, 2024 |
SC 13G/A 1 d790205dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Syros Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par valu |
|
| February 13, 2024 |
SC 13G/A 1 d749338dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 3) SYROS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0 |
|
| February 13, 2024 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.A 2 d749338dex99a.htm EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree as follows: i. Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and ii. Each of them is responsible for the timely filing of such Schedule 13G and any amendments ther |
|
| February 9, 2024 |
SYRS / Syros Pharmaceuticals, Inc. / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A 1 d771032dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87184Q107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| February 7, 2024 |
SC 13G/A 1 p24-0431sc13ga.htm SYROS PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87184Q206 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Sta |
|
| January 8, 2024 |
Exhibit 99.2 Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene — On-Track to Complete Enrollment of 190 patients for Primary Analysis in SELECT-MDS-1 Phase 3 Trial in 1Q 2024; Pivotal CR Data Expected by Mid-4Q 2024 — — Additional Data from SELECT-AML-1 Phase 2 Trial Expected in 2024; Initial Data Demonstrated 100% CR/CRi Rate and Favorable Tolerability Profile — |
|
| January 8, 2024 |
Advancing Novel Treatments for Hematologic Malignancies JP Morgan Conference January 2024 Exhibit 99. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 Syros Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 2, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99 2 p23-3048exhibit99.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without t |
|
| January 2, 2024 |
US87184Q2066 / Syros Pharmaceuticals Inc / Point72 Asset Management, L.P. Passive Investment SC 13G 1 p23-3048sc13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87184Q206 (CUSIP Number) December 21, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| December 26, 2023 |
US87184Q2066 / Syros Pharmaceuticals Inc / Samsara BioCapital, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Syros Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 87184Q206 (CUSIP Number) Abrar Hussain Samsara BioCapital GP, LLC 628 Middlefield Road Palo Alto, CA 94301 (650) 285-4270 (Name, Address |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 19, 2023 |
Exhibit 1.1 SYROS PHARMACEUTICALS, INC. 4,939,591 shares of common stock, par value $0.001 per share (the “Common Stock”) Pre-Funded Warrants to Purchase 5,242,588 Shares of Common Stock Underwriting Agreement December 18, 2023 COWEN AND COMPANY, LLC PIPER SANDLER & CO. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Cowen and Company, LLC 599 Lexington Avenue New Yo |
|
| December 19, 2023 |
Exhibit 99.1 Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants CAMBRIDGE, Mass., December 19, 2023 – Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced today that it has priced an underwritten offering of 4,939,591 share |
|
| December 19, 2023 |
Form of 2023 Pre-Funded Warrant to Purchase Common Stock Exhibit 4.1 SYROS PHARMACEUTICALS, INC. [FORM OF] PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [•] Number of Shares: [•] (subject to adjustment) Original Issue Date: December [•], 2023 Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its pe |
|
| December 19, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-271160 Prospectus supplement (To prospectus dated April 28, 2023) 4,939,591 shares of common stock Pre-funded warrants to purchase up to 5,242,588 shares of common stock We are offering 4,939,591 shares of our common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 5,24 |
|
| December 6, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 6, 2023 |
Exhibit 99.2 Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine — 100% CR/CRi Rate in Patients Treated with Tamibarotene, Venetoclax and Azacitidine Compared to 70% in Patients Randomized to Treatment with Venetoclax and Azacitidine Alone — — Triplet Regimen Continues to Demonstrate Fav |
|
| December 6, 2023 |
EX-99.1 SELECT-AML-1: Initial Randomized Data Evaluating Tamibarotene in Newly Diagnosed AML Patients Ineligible for Standard Induction Therapy December 6, 2023 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, a |
|
| November 14, 2023 |
RETIREMENT AND TRANSITION AGREEMENT This Retirement and Transition Agreement (the “Agreement”) is made by and between Nancy Simonian (the “Executive”) and Syros Pharmaceuticals, Inc. |
|
| November 14, 2023 |
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. |
|
| October 20, 2023 |
US87184Q2066 / Syros Pharmaceuticals Inc / Samsara BioCapital, L.P. - SC 13D Activist Investment SC 13D 1 tm2328773d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Syros Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 87184Q206 (CUSIP Number) Abrar Hussain Samsara BioCapital GP, LLC 628 Middlefield Road Palo Alto, CA |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 8, 2023 |
pa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q pa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2023 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 25, 2023 |
EX-99.1 Exhibit 99.1 Advancing Novel Treatments for Hematologic Malignancies May 2023 Forward-looking statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Syros and other matters, such as Syros’ clinical development plans |
|
| May 25, 2023 |
EX-99.2 Exhibit 99.2 Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting — New data support further evaluation of SY-5609 for PDAC and HR+ breast cancer and demonstrate significant potential for SY-5609 in a wide range of tumor types and combinations – — Consistent with prior guidance, exploring partnership opportunities to advance developm |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. |
|
| May 1, 2023 |
$50,000,000 SYROS PHARMACEUTICALS, INC. Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) File Number 333-271160 PROSPECTUS $50,000,000 SYROS PHARMACEUTICALS, INC. |
|
| April 26, 2023 |
Syros Pharmaceuticals, Inc. 35 CambridgePark Drive, 4th Floor Cambridge, MA 02140 April 26, 2023 CORRESP Syros Pharmaceuticals, Inc. 35 CambridgePark Drive, 4th Floor Cambridge, MA 02140 April 26, 2023 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: James McNamara Re: Syros Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-271160 Request for Accelerati |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 21, 2023 |
DEF 14A 1 d277986ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 21, 2023 |
2022 ANNUAL REPORT r rl rDear Fellow Shareholders, rl r r r r r r r lr r r r rl r l l r l rl r r ll l rr r r ll r l l rl l r r r r lllr r r ll l ll l l r r r r l r rr l rr l r r r r rll rl l r l r rl l r r rl RARA rr r l r lll r r r r r r r r r r r r r rr rl r r r l r l r r r rll r rl r l rl l r RARA rr l rll r rr l r rr r l rr r r l r r r l RARA rr r r r r rl r r l l r r rl r l rl r l r r r RARA rr r rl rl r r r r r r rr r r l r rr l ll r l rl r r r r r ll r rlr r r r r rl r r r r rl ll rl lrl r r r l l r r lr rl lr rl rr r l r r rr l rl r r l r ll r r r rr rr r r r rl l ll l l r r r l rr rr l l r l l r rr l r rl r r r rl l rr l r r r r r r l l r ll r r r l l l l rl rUNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D. |
|
| April 7, 2023 |
United States securities and exchange commission logo April 7, 2023 Gerald Quirk Chief Legal Officer Syros Pharmaceuticals, Inc. |
|
| April 6, 2023 |
As filed with the Securities and Exchange Commission on April 6, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 6, 2023 Registration No. |
|
| April 6, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Syros Pharmaceuticals, Inc. |
|
| April 6, 2023 |
Form of Subordinated Indenture EX-4.3 Exhibit 4.3 SYROS PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) |
|
| April 6, 2023 |
EX-4.4 Exhibit 4.4 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| April 6, 2023 |
Sales Agreement, dated April 6, 2023, by and between the Registrant and Cowen and Company, LLC EX-1.2 Exhibit 1.2 SYROS PHARMACEUTICALS, INC. $50,000,000 COMMON STOCK SALES AGREEMENT April 6, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees |
|
| April 6, 2023 |
EX-4.5 Exhibit 4.5 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER N |
|
| April 6, 2023 |
EX-4.2 Exhibit 4.2 SYROS PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 3 |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 2, 2023 |
2022 Inducement Stock Incentive Plan, as amended on January 30, 2023 Exhibit 10.10 SYROS PHARMACEUTICALS, INC. 2022 INDUCEMENT STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2022 Inducement Stock Incentive Plan (the “Plan”) of Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important |
|
| March 2, 2023 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Syros Pharmaceuticals, Inc. |
|
| March 2, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name of Entity Jurisdiction of Incorporation Percent Owned by the Registrant Syros Securities Corporation Massachusetts 100% Syros Pharmaceuticals (Ireland) Limited Ireland 100% Tyme Technologies, Inc. Delaware 100% Tyme, Inc. Delaware 100% |
|
| March 2, 2023 |
Exhibit 10.33 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of February 12, 2020 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral age |
|
| March 2, 2023 |
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the common stock, par value $0.001 per share (the “Common Stock”) of Syros Pharmaceuticals, Inc. (“us,” “our,” “we” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), summari |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37813 SYROS PHARMACEU |
|
| March 2, 2023 |
Power of attorney (included on the signature pages of this registration statement). S-8 As filed with the Securities and Exchange Commission on March 2, 2023 Registration No. |
|
| February 14, 2023 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completen |
|
| February 14, 2023 |
US87184Q2066 / Syros Pharmaceuticals Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d994292013g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87184Q206 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 14, 2023 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| February 13, 2023 |
SYRS / Syros Pharmaceuticals Inc / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87184Q107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| January 30, 2023 |
SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Syros Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securitie |
|
| January 25, 2023 |
SC 13G 1 p23-0257sc13g.htm SYROS PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87184Q206 (CUSIP Number) January 15, 2023 (Date of Event Which Requires Filing of This Statement) |
|
| January 9, 2023 |
Exhibit 99.2 Syros Announces Clinical Updates and 2023 Strategic Priorities — Expect to Complete Enrollment in SELECT-MDS-1 Phase 3 Trial in 4Q 2023; Data Expected in 3Q 2024 — — On Track to Initiate Randomized Portion of SELECT-AML-1 Phase 2 Trial in 1Q 2023; Initial Data Expected 4Q 2023 — — Entering 2023 in Strong Financial Position, with Cash into 2Q 2025 — CAMBRIDGE, Mass., January 9, 2023 – |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 9, 2023 |
Advancing Novel Treatments for Hematologic Malignancies January 2023 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Syros and other matters, such as Syros’ clinical development plans, in |
|
| December 20, 2022 |
December 20, 2022 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Lauren Hamill Tim Buchmiller Re: Syros Pharmaceuticals, Inc. |
|
| December 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 Syros Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37813 45-3772460 (State or other jurisdiction of |
|
| December 12, 2022 |
EX-99.1 An Expression Makes a World of Difference December 2022 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Syros and other matters, such as Syros’ clinical development plans, includi |
|
| December 12, 2022 |
EX-99.2 Exhibit 99.2 Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial – 83% composite complete response rate in newly diagnosed unfit AML patients with RARA gene overexpression – – Initial safety and clinical activity profile of the triplet regimen su |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2022 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2022 Syros Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37813 45-3772460 (State or other jurisdiction of |
|
| December 1, 2022 |
As filed with the Securities and Exchange Commission on November 30, 2022 S-3/A Table of Contents As filed with the Securities and Exchange Commission on November 30, 2022 Registration No. |
|
| December 1, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS EX-99.3 Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Explanatory Note On July 3, 2022, Syros Pharmaceuticals, Inc., a Delaware corporation (“Syros”), Tack Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Syros (“Merger Sub”), and Tyme Technologies, Inc., a Delaware corporation (“Tyme”), entered into an Agreement and Plan of Merger (the “Merger |
|
| November 30, 2022 |
CORRESP 1 filename1.htm Cynthia T. Mazareas +1 617 526 6393 (t) +1 617 526 5000 (f) [email protected] November 30, 2022 Via EDGAR Submission Securities and Exchange Commission Division of Corporation Finance – Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Lauren Hamill Tim Buchmiller Re: Syros Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed O |
|
| November 14, 2022 |
Form of Restricted Stock Agreement Under 2022 Equity Incentive Plan Exhibit 10.12 SYROS PHARMACEUTICALS, INC. Restricted Stock Agreement Syros Pharmaceuticals, Inc. (the ?Company?) hereby grants the following award of restricted stock pursuant to its 2022 Equity Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the ?Participant?): Grant Date: Number of shares of the restricted common stock, $0.001 p |
|
| November 14, 2022 |
Exhibit 10.8 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into as of August 31, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capacity, ?Collateral Agent?) |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. |
|
| November 14, 2022 |
Form of Stock Option Agreement Under 2022 Equity Incentive Plan Exhibit 10.10 SYROS PHARMACEUTICALS, INC. STOCK OPTION AGREEMENT Syros Pharmaceuticals, Inc. (the ?Company?) hereby grants the following stock option pursuant to its 2022 Equity Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the ?Participant?): Grant Date: Incentive Stock Option or Nonstatutory Stock Option: Number of shares of th |
|
| November 14, 2022 |
Amended and Restated Director Compensation Policy Exhibit 10.13 SYROS PHARMACEUTICALS, INC. AMENDED AND RESTATED DIRECTOR COMPENSATION POLICY Non-employee directors shall receive the following compensation for their service as members of the Board of Directors (the ?Board?) of Syros Pharmaceuticals, Inc. (the ?Company?). Director Compensation Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract |
|
| November 14, 2022 |
Form of Restricted Stock Unit Agreement Under 2022 Equity Incentive Plan Exhibit 10.11 SYROS PHARMACEUTICALS, INC. Restricted Stock Unit Agreement Syros Pharmaceuticals, Inc. (the ?Company?) hereby grants the following restricted stock units pursuant to its 2022 Equity Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the ?Participant?): Grant Date: Number of restricted stock units (?RSUs?) granted: Numb |
|
| November 14, 2022 |
Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF SYROS PHARMACEUTICALS, INC. (originally incorporated on November 9, 2011 under the name LS22, Inc.) First: The name of the Corporation is Syros Pharmaceuticals, Inc. Second: The address of the Corporation?s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, |
|
| November 10, 2022 |
SYRS / Syros Pharmaceuticals Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No.8 SYROS PHARMACEUTICALS INC COMMON STOCK Cusip #87184Q206 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #87184Q206 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 104,505 Item 6: 0 Item 7: 104,614 Item 8: 0 Item 9: 104,614 Item 11: 0. |
|
| October 28, 2022 |
United States securities and exchange commission logo October 28, 2022 Gerald E. Quirk, Esq. Chief Legal Officer Syros Pharmaceuticals, Inc. 35 Cambridge Park Drive, 4th Floor Cambridge, MA 02140 Re: Syros Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed October 14, 2022 File No. 333-267888 Dear Gerald E. Quirk: We have limited our review of your registration statement to those issue |
|
| October 14, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Syros Pharmaceuticals, Inc. |
|
| October 14, 2022 |
As filed with the Securities and Exchange Commission on October 14, 2022 Table of Contents As filed with the Securities and Exchange Commission on October 14, 2022 Registration No. |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 Syros Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37813 45-3772460 (State or other jurisdiction of incorporation) (Commis |
|
| September 20, 2022 |
SYRS / Syros Pharmaceuticals Inc / Avidity Partners Management LP Passive Investment SC 13G 1 d976398913g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87184Q206 (CUSIP Number) September 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| September 19, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) SYROS PHARMACEUTICALS, INC. |
|
| September 19, 2022 |
SYRS / Syros Pharmaceuticals Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 19, 2022 |
As filed with the Securities and Exchange Commission on September 19, 2022 As filed with the Securities and Exchange Commission on September 19, 2022 Registration No. |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 Syros Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37813 45-3772460 (State or other jurisdiction of incorporation) (Com |
|
| September 16, 2022 |
Exhibit 99.1 Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement ? Cash and cash equivalents of approximately $240 million after giving effect to close ? ? Timothy C. Tyson and Andrew Oh join Syros Board of Directors ? CAMBRIDGE, Mass., Sept. 16, 2022 ? Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the express |
|
| September 16, 2022 |
As filed with the Securities and Exchange Commission on September 16, 2022 As filed with the Securities and Exchange Commission on September 16, 2022 Registration No. |
|
| September 16, 2022 |
Calculation of Filing Fee Tables. EX-FILING FEES 4 d259216dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) SYROS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Ra |
|
| September 16, 2022 |
SYRS / Syros Pharmaceuticals Inc / TYME TECHNOLOGIES, INC. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87184Q107 (CUSIP Number) Tyme Technologies, Inc. 1 Pluckemin Way, Suite 103 Bedminster NJ 07921 (212) 461-2315 (Name, Address and Telephone Number of Person |
|
| September 16, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF SYROS PHARMACEUTICALS, INC. Syros Pharmaceuticals, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), does hereby certify as follows: 1. The name of the Corporation is Syros Pharma |
|
| September 16, 2022 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF SYROS PHARMACEUTICALS, INC. Syros Pharmaceuticals, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), does hereby certify as follows: 1. The name of the Corporation is Syros Pharma |
|
| September 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 SYROS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37813 45-3772460 (State or other jurisdiction of incorporation) (Com |
|
| September 15, 2022 |
425 1 d369438d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 SYROS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37813 45-3772460 (State or other jurisdict |
|
| September 15, 2022 |
Exhibit 99.2 Syros and Tyme Technologies Announce Stockholder Approval of Merger ? Combined Company to Trade on Nasdaq Under Ticker ?SYRS? ? ? Syros Announces 1-for-10 Reverse Stock Split of Common Stock ? CAMBRIDGE, Mass. & BEDMINSTER, N.J., Sept. 15, 2022 ? Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technolog |
|
| September 15, 2022 |
SYROS PHARMACEUTICALS, INC. 2022 EQUITY INCENTIVE PLAN Exhibit 99.1 SYROS PHARMACEUTICALS, INC. 2022 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this 2022 Equity Incentive Plan (the ?Plan?) of Syros Pharmaceuticals, Inc. a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the C |
|
| September 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 SYROS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37813 45-3772460 (State or other jurisdiction of incorporation) (Comm |
|
| September 2, 2022 |
425 1 d357580d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 SYROS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37813 45-3772460 (State or other jurisdicti |
|
| August 9, 2022 |
PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT Filed Pursuant to Rule 424(b)(3) Registration No. 333-266184 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of Syros Pharmaceuticals, Inc. and Tyme Technologies, Inc., Syros Pharmaceuticals, Inc., a Delaware corporation, or Syros, and Tyme Technologies, Inc., a Delaware corporation, or Tyme, entered into an Agreement and Plan of Merger, or the Merger Agreement, on July 3, 2022, pu |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. |
|
| August 4, 2022 |
CORRESP 1 filename1.htm August 4, 2022 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Conlon Danberg Re: Syros Pharmaceuticals, Inc. Registration Statement on Form S-4 File No. 333-266184 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Syros Ph |
|
| August 1, 2022 |
Form of Preliminary Proxy Card of Tyme Technologies, Inc. Exhibit 99.2 YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. IMMEDIATE Vote by - Internet 24 Hours - a QUICK Day, 7 Days a Week EASY or by Mail TYME TECHNOLOGIES, INC. to Your vote Internet your shares vote authorizes in the same the manner named as proxies if you card marked, . Votes signed, submitted dated and electronically returned your over proxy the Internet Time, on September must be received 14 |
|
| August 1, 2022 |
Form of Preliminary Proxy Card of Syros Pharmaceuticals, Inc. Exhibit 99.1 SYRS VOTE 000004 ENDORSEMENT LINE SACKPACK MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 C123456789 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext Using a black ink pen, mark your votes with an X as shown in this example. X Please do not write outside the designated areas. Your vote m |
|
| August 1, 2022 |
As filed with the Securities and Exchange Commission on August 1, 2022 As filed with the Securities and Exchange Commission on August 1, 2022 Registration No. |
|
| July 20, 2022 |
United States securities and exchange commission logo July 20, 2022 Nancy Simonian, M. |
|
| July 18, 2022 |
Consent of Piper Sandler & Co. Exhibit 99.3 CONSENT OF PIPER SANDLER & CO. We hereby consent to the inclusion of our opinion letter, dated July 1, 2022, addressed to the Board of Directors of Syros Pharmaceuticals, Inc. (the ?Company?), included as Annex B to the proxy statement/prospectus contained in that certain registration statement of the Company, on Form S-4 (the ?Registration Statement?) relating to the proposed agreeme |
|
| July 18, 2022 |
July 18, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 18, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) SYROS PHARMACEUTICALS, INC. |
|
| July 18, 2022 |
Form of Syros Pharmaceuticals, Inc. 2022 Equity Incentive Plan Exhibit 10.5 SYROS PHARMACEUTICALS, INC. 2022 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this 2022 Equity Incentive Plan (the ?Plan?) of Syros Pharmaceuticals, Inc. a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the C |
|
| July 18, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on July 18, 2022 Registration No. |
|
| July 18, 2022 |
Consent of Moelis & Company LLC Exhibit 99.4 CONSENT OF MOELIS & COMPANY LLC July 18, 2022 Board of Directors Tyme Technologies, Inc. 1 Pluckemin Way Bedminster, NJ 07921 Members of the Board: We hereby consent to the inclusion of our opinion letter, dated July 2, 2021, to the Board of Directors of Tyme Technologies, Inc. (?Tyme?) as Annex C to, and to the references thereto under the headings ?Prospectus Summary?Opinion of Moel |
|
| July 13, 2022 |
Exhibit 1 AGREEMENT AND PLAN OF MERGER by and among SYROS PHARMACEUTICALS, INC., TACK ACQUISITION CORP., and TYME TECHNOLOGIES, INC. Dated as of July 3, 2022 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 1.1 Effective Time of the Merger 2 1.2 Closing 2 1.3 Effects of the Merger 2 1.4 Directors and Officers of the Surviving Corporation 2 1.5 Syros Matters 2 ARTICLE II CONVERSION OF SECURITIES 3 2.1 |
|
| July 13, 2022 |
TYME / Tyme Technologies Inc / Syros Pharmaceuticals, Inc. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Tyme Technologies, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90238J103 (CUSIP Number) Syros Pharmaceuticals, Inc. 35 CambridgePark Drive, 4th Floor Cambridge, MA 02140 (617) 744-1340 (Name, Address and Telephone Number of Person Authorized to Receiv |
|
| July 13, 2022 |
TYME TECHNOLOGIES, INC. [FORM OF] SUPPORT AGREEMENT Exhibit 2 TYME TECHNOLOGIES, INC. [FORM OF] SUPPORT AGREEMENT This Support Agreement (this ?Agreement?) is made and entered into as of [?], 2022, by and among Syros Pharmaceuticals, Inc. a Delaware corporation (?Syros?), Tyme Technologies, Inc., a Delaware corporation (?Tyme?), and the undersigned stockholder (the ?Stockholder?) of Tyme. RECITALS WHEREAS, concurrently with the execution and delive |
|
| July 13, 2022 |
SYRS / Syros Pharmaceuticals Inc / TYME TECHNOLOGIES, INC. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 87184Q107 (CUSIP Number) Tyme Technologies, Inc. 1 Pluckemin Way, Suite 103 Bedminster NJ 07921 (212) 461-2315 (Name, Address and Telephone Number of Person Authorized to Receive Notic |
|
| July 8, 2022 |
SYRS / Syros Pharmaceuticals Inc / BlackRock Inc. Passive Investment us87184q1076070822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Syros Pharmaceuticals, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 87184Q107 - (CUSIP Number) June 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| July 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2022 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 6, 2022 |
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us Exhibit 99.1 REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us ?2022 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. ?Refinitiv? and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. CORPORATE PARTICIPANTS Courtney So |
|
| July 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2022 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 6, 2022 |
An Expression Makes a World of Difference July 2022 Exhibit 99.2 Forward-looking statements Forward Looking Statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act concerning Syros, TYME, the proposed transactions and other matters. These statements may di |
|
| July 5, 2022 |
Exhibit 10.4 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of July 3, 2022 (the ?Execution Date?) by and among Syros Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and the Investors identified on Exhibit A attached hereto (each an ?Investor? and collectively the ?Investors?). RECITALS A. On or prior to the date hereo |
|
| July 5, 2022 |
Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of July 3, 2022 by and among Syros Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and the ?Investors? named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of July 3, 2022 (the ?Purchase Agreement?). Capitali |
|
| July 5, 2022 |
Exhibit 10.7 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into as of July 3, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capacity, ?Collateral Agent?), the |
|
| July 5, 2022 |
Form of 2022 Warrant to Purchase Common Stock or 2022 Pre-Funded Warrants Exhibit 4.1 THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (i) S |
|
| July 5, 2022 |
Exhibit 99.1 Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros? Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023 Syr |
|
| July 5, 2022 |
Exhibit 10.1 SYROS PHARMACEUTICALS, INC. [FORM OF] SUPPORT AGREEMENT This Support Agreement (this ?Agreement?) is made and entered into as of [?], 2022, by and among Tyme Technologies, Inc. a Delaware corporation (?Tyme?), Syros Pharmaceuticals, Inc., a Delaware corporation (?Syros?), and the undersigned stockholder (the ?Stockholder?) of Syros. RECITALS WHEREAS, concurrently with the execution an |
|
| July 5, 2022 |
Exhibit 10.2 TYME TECHNOLOGIES, INC. [FORM OF] SUPPORT AGREEMENT This Support Agreement (this ?Agreement?) is made and entered into as of [?], 2022, by and among Syros Pharmaceuticals, Inc. a Delaware corporation (?Syros?), Tyme Technologies, Inc., a Delaware corporation (?Tyme?), and the undersigned stockholder (the ?Stockholder?) of Tyme. RECITALS WHEREAS, concurrently with the execution and del |
|
| July 5, 2022 |
Exhibit 10.6 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made as of July 3, 2022 by and between Syros Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the ?Investors?). Unless otherwise defined herein, capitalized terms used in this Agreeme |
|
| July 5, 2022 |
Exhibit 4.2 THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (i) S |
|
| July 5, 2022 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among SYROS PHARMACEUTICALS, INC., TACK ACQUISITION CORP., and TYME TECHNOLOGIES, INC. Dated as of July 3, 2022 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 1.1 Effective Time of the Merger 2 1.2 Closing 2 1.3 Effects of the Merger 2 1.4 Directors and Officers of the Surviving Corporation 2 1.5 Syros Matters 2 ARTICLE II CONVERSION OF SECURITIES 3 2 |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2022 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2022 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 5, 2022 |
Exhibit 10.3 SYROS PHARMACEUTICALS, INC. [FORM OF] LOCK-UP AGREEMENT [?], 2022 Syros Pharmaceuticals, Inc. 35 CambridgePark Drive Cambridge, Massachusetts 02140 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this ?Lock-Up Agreement?) understands that Syros Pharmaceuticals, Inc., a Delaware corporation (?Syros?), has entered into an Agreement and Plan of Merger, dated as |
|
| June 7, 2022 |
EX-99.1 2 d537191dex991.htm EX-99.1 An Expression Makes a World of Difference June 2022 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, in |
|
| June 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 16, 2022 |
Exhibit 10.1 CONFIDENTIAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. MASTER COLLABORATION AGREEMENT for Companion Diagnostics BetweenSyros Pharmaceuticals, Inc. 35 CambridgePark Drive Cambridge, MA 02140 hereinafter |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. |
|
| April 21, 2022 |
DEF 14A 1 d279732ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 11, 2022 |
SYRS / Syros Pharmaceuticals Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No.7 SYROS PHARMACEUTICALS INC COMMON STOCK Cusip #87184Q107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #87184Q107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,797,042 Item 6: 0 Item 7: 5,797,876 Item 8: 0 Item 9: 5,797,876 Item |
|
| March 15, 2022 |
2022 Inducement Stock Incentive Plan Exhibit 10.10 SYROS PHARMACEUTICALS, INC. 2022 INDUCEMENT STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2022 Inducement Stock Incentive Plan (the ?Plan?) of Syros Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important |
|
| March 15, 2022 |
Form of Restricted Stock Unit Agreement under 2022 Inducement Stock Incentive Plan Exhibit 10.12 Syros Pharmaceuticals, Inc. RESTRICTED STOCK UNIT AGREEMENT Granted under 2022 Inducement Stock Incentive Plan Syros Pharmaceuticals, Inc. (the ?Company?) hereby grants the following restricted stock units pursuant to its 2022 Inducement Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the ?Participant?): Grant |
|
| March 15, 2022 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) SYROS PHARMACEUTICALS, INC. |
|
| March 15, 2022 |
Form of Nonstatutory Stock Option Agreement under 2022 Inducement Stock Incentive Plan Exhibit 10.11 SYROS PHARMACEUTICALS, INC. NONSTATUTORY STOCK OPTION AGREEMENT Granted under 2022 Inducement Stock Incentive Plan Syros Pharmaceuticals, Inc. (the ?Company?) hereby grants the following stock option pursuant to its 2022 Inducement Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the ?Participant?): Grant Date: N |
|
| March 15, 2022 |
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the common stock, par value $0.001 per share (the ?Common Stock?) of Syros Pharmaceuticals, Inc. (?us,? ?our,? ?we? or the ?Company?), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), summari |
|
| March 15, 2022 |
As filed with the Securities and Exchange Commission on March 15, 2022 As filed with the Securities and Exchange Commission on March 15, 2022 Registration No. |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37813 SYROS PHARMACEU |
|
| March 8, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240. |
|
| February 14, 2022 |
SC 13G/A 1 brhc10033974sc13ga.htm SC13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 87184Q107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 11, 2022 |
SYRS / Syros Pharmaceuticals Inc / Artal International S.C.A. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 87184Q107 (CUSIP Number) February 2, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 11, 2022 |
Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Syros Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 87184Q |
|
| February 11, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common Stock, par value $0. |
|
| February 9, 2022 |
SYRS / Syros Pharmaceuticals Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 6 SYROS PHARMACEUTICALS INC COMMON STOCK Cusip #87184Q107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #87184Q107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,575,255 Item 6: 0 Item 7: 9,332,797 Item 8: 0 Item 9: 9,332,797 Item |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Syros Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 87184Q107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 3, 2022 |
SYRS / Syros Pharmaceuticals Inc / BlackRock Inc. Passive Investment us87184q1076020322.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) Syros Pharmaceuticals, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 87184Q107 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| January 10, 2022 |
An Expression Makes a World of Difference January 2022 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our |
|
| January 10, 2022 |
Exhibit 99.2 Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company Initiated Expansion Cohort of SY-5609 with Chemotherapy in Pancreatic Cancer Patients Expects to Report Data from Three Clinical Trials Across Hematology and Selective CDK Inhibitor Programs in 2022 Now Expects to Initiate Phase 1 Single Agent Trial of SY-5609 in |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. |
|
| November 5, 2021 |
Exhibit 10.2 September 10, 2021 Conley Chee Delivered via Email Dear Conley: On behalf of Syros Pharmaceuticals, Inc. (the ?Company?), I am pleased to extend the following offer and set forth the terms of your employment with the Company: 1.You will be employed to serve on a full-time basis as Chief Commercial Officer, effective September 27, 2021. As Chief Commercial Officer, you will report to t |
|
| October 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 13, 2021 |
Offer Letter dated September 8, 2021 by and between the Registrant and Jason Haas Exhibit 10.1 35 CambridgePark Drive, 4th Floor Cambridge, MA 02140 syros.com September 8, 2021 Jason Haas Delivered via Email Dear Jason: On behalf of Syros Pharmaceuticals, Inc. (the ?Company?), I am pleased to extend the following offer and set forth the terms of your employment with the Company: 1. You will be employed to serve on a full-time basis as Chief Financial Officer, effective October |
|
| October 13, 2021 |
Form of Nonstatutory Stock Option Agreement for Inducement Awards. Filed herewith. Exhibit 10.2 SYROS PHARMACEUTICALS, INC. INDUCEMENT STOCK OPTION AGREEMENT Syros Pharmaceuticals, Inc. (the ?Company?) hereby grants the following stock option. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the ?Participant?): Grant Date: Number of shares of the Company?s Common Stock subject to this option (?Shares?): Option exercise price per |
|
| September 20, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2021 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 20, 2021 |
SY-5609 Phase 1 Dose-Escalation Data and Next Steps September 20, 2021 Exhibit 99. |
|
| September 20, 2021 |
Exhibit 99.2 Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer Updated Dose-Escalation Data Demonstrate Clinical Activity in Heavily Pre-treated Patients Across Multiple Tumor Types Plan to Initiate Expansion Evaluating SY-5609 in Combination with Chemotherapy in Pancreatic Cancer in 4Q 2021 Plan |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2021 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. |
|
| August 5, 2021 |
Exhibit 3.2 SECOND AMENDED AND RESTATED BY-LAWS OF SYROS PHARMACEUTICALS, INC. TABLE OF CONTENTS Page Article I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Record Date for Stockholder Meetings 1 1.5 Notice of Meetings 2 1.6 Voting List 2 1.7 Quorum 2 1.8 Adjournments 3 1.9 Voting and Proxies 3 1.10 Action at Meeting 3 1.11 Nomination of Directors. 3 1.12 |
|
| June 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 26, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 26, 2021 |
An Expression Makes a World of Difference May 2021 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our stra |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37813 SYROS PHARMACEUTICALS, INC. |
|
| May 6, 2021 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[**]?. AMENDMENT NO. 1 TO AMENDED AND RESTATED CANCER LICENSE AGREEMENT This Amendment to Amended and Restated License Agreement (this ?Amendment?) is made as of January 8, |
|
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| March 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37813 SYROS PHARMACEU |
|
| March 4, 2021 |
Description of Securities Registered under Section 12 of the Exchange Act Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the common stock, par value $0.001 per share (the ?Common Stock?) of Syros Pharmaceuticals, Inc. (?us,? ?our,? ?we? or the ?Company?), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), summari |
|
| March 4, 2021 |
As filed with the Securities and Exchange Commission on March 4, 2021 Registration No. |
|
| February 25, 2021 |
An Expression Makes a World of Difference February 2021 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our |
|
| February 25, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 Syros Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37813 45-3772460 (State or Other Jurisdiction of Incorporation) (Comm |
